Spine BioPharma, Inc., a development stage company committed to non-opiate, non-surgical therapies for Degenerative Disc ...

Canaccord raised the firm’s price target on Okta (OKTA) to $100 from $94 and keeps a Hold rating on the shares. The firm said they reported ...

Would you like to be notified of the latest news and updates on the stock market?

Canaccord Genuity analyst Tim Huff reiterated a Buy rating on Antofagasta (ANTO – Research Report) yesterday and set a price target of ...

The semi-finals of Manx Hockey Association’s men’s and women’s cup, plate and bowl competitions took place on Saturday, with ...

TTEC (NASDAQ:TTEC – Free Report) had its target price reduced by Canaccord Genuity Group from $4.50 to $3.50 in a research ...

Whales with a lot of money to spend have taken a noticeably bullish stance on Core Scientific. If we consider the specifics ...

The latest Market Talks covering Basic Materials. Published exclusively on Dow Jones Newswires at 4:20 ET, 12:20 ET and 16:50 ...

Cardinal Energy Ltd. (TSX: CJ) ("Cardinal" or the "Company") is pleased to announce that it has completed its previously ...

The looming end to Australia’s $40bn hybrid securities market represents a big opportunity for stockbroking veteran Geoff ...

Clover Health Investments (NASDAQ:CLOV – Free Report) had its target price raised by Canaccord Genuity Group from $4.20 to $4.50 in a research report report published on Monday morning,Benzinga ...

Inside the Market’s roundup of some of today’s key analyst actions. Following first-quarter 2025 earnings season for Canadian ...